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Multiple vaccines have been developed that offer protec-tion against COVID-19 by generating immune responses against the spike antigen of SARS-CoV-2. On 8 December 
2020, the United Kingdom (UK) started its national vaccination pro-
gramme with the Pfizer–BioNTech BNT162b2 vaccine1, followed 
by the approval of the Oxford–AstraZeneca ChAdOx1 nCoV-19 
vaccine, first used outside a clinical trial on 4 January 2021 (ref. 2). 
Both vaccines have been widely used in the UK.
Vaccines were initially administered to priority groups, includ-
ing care home residents, people >80 years old, healthcare workers 
and those clinically vulnerable (≥16 years), and then offered to the 
rest of the adult (≥18 years) population in decreasing age order3. To 
maximize initial coverage, in early January 2021, the dosing interval 
was extended to 12 weeks for all vaccines, regardless of the licensed 
dosing schedule. Up until 6 April 2021, 31.7 million people (60.2% 
of the population aged ≥18 years) have been given a first dose, 
and 5.7 million people (10.8%) have received two vaccine doses 
(https://coronavirus.data.gov.uk/details/vaccinations).
The efficacy of the ChAdOx1 and BNT162b2 vaccines against 
symptomatic laboratory-confirmed SARS-CoV-2 infection has 
been reported in large randomized controlled clinical trials as 52% 
(95% confidence interval (CI) = 30–86%) after the first dose and 
95% (95% CI = 90–98%) after the second dose of BNT162b2 (ref. 4), 
and 70% (95% CI = 55–81%) after the second dose of ChAdOx1 
(ref. 5). Several studies have examined the immunogenicity of vac-
cines in healthcare workers, who were typically the earliest groups 
to be vaccinated. A study of 3,610 healthcare workers found that 
99.5% and 97.1% seroconverted after a single dose of BNT162b2 or 
ChAdOx1, respectively, and that higher quantitative immunoglobu-
lin G (IgG) levels were achieved in previously infected individuals6. 
Other studies have also found that single-dose BNT162b2 elicited 
higher antibody levels in previously seropositive individuals, levels 
that were comparable to those after two doses of vaccines in sero-
negative individuals7–9. Outside trials, there are limited data on 
post-vaccine antibody responses in other groups, especially older 
adults who were underrepresented in the ChAdOx1 trial5. A study of 
185 individuals aged >70 years showed high seropositivity after one 
or two BNT162b2 doses10. Another study, of 100 individuals aged 
80–100 years, showed almost universal high antibody responses 3 
weeks after a single dose of BNT162b2, with spike-specific cellular 
responses in 63% of participants11. However, the representativeness 
of these small cohorts is unclear.
Real-world data provide information on populations who may 
not participate in clinical trials and can be used to assess the efficacy 
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of interventions as deployed. We used the UK’s national COVID-19 
Infection Survey (ISRCTN21086382), which includes a representa-
tive sample of households and has longitudinal follow-up, to study 
population-wide anti-trimeric spike IgG antibody responses after 
SARS-CoV-2 vaccination by time since vaccination, considering 
the vaccine type (BNT162b2 or ChAdOx1), the number of doses 
received, the presence or absence of prior SARS-CoV-2 infection 
and demographic factors. Our results build on the REACT-2 study, 
a serial cross-sectional UK study of antibody responses using a 
binary point-of-care lateral flow assay12. Specifically, we investigate 
longitudinal data in the same individuals with a validated quantita-
tive laboratory antibody assay, which has previously been shown to 
correlate with neutralizing activity (correlation coefficient of 0.76)13, 
allowing the assay to act as a potential correlate of protection based 
on the strong association between quantitative neutralizing activity 
and protection from infection14. Supporting this, quantitative read-
ings from the assay are associated with protection from infection in 
those previously infected15.
Results
In all, 45,965 participants aged ≥16 years from the general popu-
lation who were first vaccinated between 8 December 2020 and 6 
April 2021 contributed a total of 111,360 SARS-CoV-2 anti-spike 
IgG measurements taken at any point between 91 days before the 
first vaccination date up until 6 April 2021 (Extended Data Fig. 1). 
The median (interquartile (IQR)) age was 64 (54–71) years, and 
25,330 (55.1%) were female. A total of 2,745 (6.0%) were health-
care workers, and 15,334 (33.4%) had a long-term health condition 
(Supplementary Table 1). In all, 5,834 (12.7%) participants with a 
SARS-CoV-2 PCR-positive study nose/throat swab or anti-spike 
IgG-positive study antibody result at any time before vaccination 
were considered to have been previously infected with SARS-CoV-2, 
irrespective of whether they had reported previous symptoms or 
not. Using this definition, 3,767 (8.2%) and 2,067 (4.5%) previ-
ously infected participants then received one dose of ChAdOx1 or 
BNT162b2, respectively. A total of 23,368 (50.8%), 14,894 (32.4%) 
and 1,869 (4.1%) participants without evidence of prior infection 
received one dose of ChAdOx1, one dose of BNT162b2 or two doses 
of BNT162b2, respectively. Among 1,869 (4.1%) participants with-
out evidence of prior infection who received two doses of BNT162b2, 
the median (IQR) duration between two doses was 31 (21–47) days, 
with 1,020 (54.6%) ≤31 days (Fig. 1f and Supplementary Table 1). 
Participant characteristics varied across the different vaccination 
groups, which generally reflected vaccine prioritization, with pro-
portionately more healthcare workers and the oldest individuals 
having received two doses of BNT162b2.
Antibody positivity after vaccination. In participants without evi-
dence of prior infection, models of binary (positive versus negative) 
post-vaccine antibody responses showed that positive anti-spike 
IgG results increased over the 2–4 weeks after the first vaccination 
and varied significantly by age (Fig. 1 and Extended Data Fig. 2, 
with observed numbers/percentages in Extended Data Figs. 3–7). 
Fewer older participants were seropositive after receiving a single 
dose of ChAdOx1 or BNT162b2. For example, the estimated per-
centage of seropositive 80 year olds was 74% (95% CI = 66–80%) 
and 85% (95% CI = 80–89%) 28 days after the first vaccination with 
ChAdOx1 or BNT162b2, respectively, compared with 79% (95% 
CI = 75–83%) and 91% (95% CI = 89–93%), respectively, for 60 year 
olds and 84% (95% CI = 76–89%) and 95% (95% CI = 92–97%), 
respectively, for 40 year olds (Supplementary Table 2). In contrast, 
two doses of BNT162b2 achieved >90% seropositivity 28–72 days 
after the first vaccination regardless of age, although there was some 
evidence of waning in those only receiving a first BNT162b2 dose 
at older ages. There was no evidence of differences in seropositivity 
rates 14–42 days after the first vaccine in those of younger ages 
(for example, 20 and 40 years) receiving one dose or two doses of 
BNT162b2, but greater rates of seroconversion were seen in older 
individuals (for example, 80 years) receiving two doses (Extended 
Data Fig. 2). There was no evidence of seropositivity declines 
following the first vaccine dose in older individuals receiving a 
single dose of ChAdOx1.
In participants with prior evidence of infection, before vaccina-
tion, younger participants were more likely to be seropositive. For 
example, on the day of vaccination 90% (95% CI = 82–95%) for 
20 year olds, 85% (95% CI = 80–88%) for 40 year olds, 78% (95% 
CI = 75–82%) for 60 year olds and 70% (95% CI = 61–78%) for 80 
year olds receiving ChAdOx1 were seropositive (Supplementary 
Table 2; the same trend occurred for BNT162b2). A high percentage 
of participants achieved positive antibody responses 28 days after 
vaccination (≥94%) regardless of age and the vaccine given, and 
the rate was similar to the positivity rate in participants without 
prior infection who received two doses of BNT162b2 (Extended 
Data Fig. 2).
Associations with initial antibody response in those without 
evidence of prior infection. A total of 28,144 participants had an 
anti-spike IgG measurement 14–60 days after their first ChAdOx1 
or BNT162b2 vaccination, of whom 24,977 (88.7%) had no evidence 
of prior infection and were included in a separate logistic regression 
analysis to investigate associations with antibody positivity. In all, 
20,505 (82.1%) had a positive post-vaccine anti-spike IgG result. 
Age, sex, vaccine type, ethnicity, social deprivation, healthcare roles 
and long-term health conditions were associated with seropositivity 
after vaccination (Table 1). Consistent with the data presented in 
Fig. 1, anti-spike IgG positivity decreased with older age, and the 
association was nonlinear, with seropositivity dropping faster for 
those aged >75 years (Fig. 2a,b). There was evidence of effect modi-
fication between age and sex, whereby at younger ages (30–55 years), 
similar rates of seroconversion were seen in males and females (for 
example, in 40 year olds, adjusted odds ratio (aOR) = 0.91 [95% CI = 
0.68–1.22]), but at older ages (>60 years) males were less likely 
to seroconvert (for example, aOR = 0.65 [0.59–0.72] for 70 year 
olds) (Fig. 2a; interaction P = 0.02). Seroconversion by 60 days 
was less common following ChAdOx1 than after BNT162b2 
vaccination (aOR = 0.47 [95% CI = 0.44–0.51]), while receiving two 
doses of BNT162b2 increased seroconversion compared with one 
BNT162b2 dose (aOR = 2.11 [1.69–2.66]). Patient-facing healthcare 
workers were more likely to be anti-spike IgG positive by 60 days 
post-vaccination (aOR = 1.63 [1.29–2.08]), and participants who 
had long-term health conditions were less likely (aOR = 0.64 [0.60–
0.69]). There was evidence of greater seropositivity post-vaccination 
in participants from non-white ethnic groups (aOR = 1.54 [1.27–
1.90]). A 10-unit increase in deprivation percentile (that is, decrease 
in deprivation) resulted in higher seropositivity post-vaccination 
(aOR = 1.28 [1.13–1.46]). There was no evidence of independent 
associations between antibody positivity and household size or 
working in social care or long-term care facilities.
Quantitative antibody response after vaccination. In partici-
pants without evidence of prior infection, quantitative anti-spike 
IgG levels followed similar patterns to binary IgG positivity 
post-vaccination (Figs. 3 and 4 and Extended Data Fig. 8). 
Following a single dose of BNT162b2 or ChAdOx1, older partici-
pants reached lower peak levels and levels rose more slowly than 
in those of younger ages. Anti-spike IgG levels were initially lower 
after a single dose of ChAdOx1 than after BNT162b2. For example, 
28 days post-vaccine, the following IgG levels (in ng ml–1 equiva-
lents, with 95% CIs in parentheses) were reported for ChAdOx1 and 
BNT162b2, respectively: 73 (65–81) and 113 (104–123) for 80 year 
olds; 94 (87–100) and 163 (153–175) for 60 year olds; 113 (99–129) 
and 236 (214–261); for 40 year olds; and 127 (94–171) and 334 
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(266–420) for 20 year olds (Supplementary Table 3). As context, in 
a prior study15, protection from re-infection began to rise at anti-
body titres of ~20 ng ml–1, and increased as antibody titres rose to 
~250 ng ml–1, with 50% protection against any PCR-positive result 
(symptomatic or asymptomatic) achieved at titres of 28 ng ml–1. 
The rate of increase in antibody levels was also slightly slower fol-
lowing the ChAdOx1 vaccine. For example, the estimated mean 
time to reaching the threshold for antibody positivity after the first 
vaccine in 40 year olds was 10 days after receiving BNT162b2 but 
14 days after receiving ChAdOx1 (Fig. 3). However, antibody levels 
gradually decreased from ~35 days post-vaccination in participants 
receiving a single dose of BNT162b2 (Fig. 3), while there was no 
evidence of decrease in those receiving a single ChAdOx1 dose up 
to 49 days post-vaccination. Hence, differences in mean antibody 
levels between single doses of the two vaccines attenuated over time, 
particularly at older ages (Supplementary Table 3).
For two doses of BNT162b2, high anti-spike IgG levels were 
achieved 28 days after the first vaccination regardless of age 
(Supplementary Table 3). The anti-spike IgG levels after receiving 
one dose of BNT162b2 compared with two doses were similar in 
younger ages but were substantially attenuated at older ages, with 
differences starting earlier after the first vaccine and attenuating 
more rapidly with increasing age (Fig. 4).
In participants with evidence of prior infection, while vaccina-
tion increased antibody levels at all ages, the absolute increases were 
more modest. Older previously infected participants had lower 
IgG levels compared with younger ages before and after vaccina-
tion (Fig. 3). There was no evidence of a difference in post-vaccine 
response after prior infection between those receiving BNT162b2 
or ChAdOx1 (Figs. 3 and 4). At intermediate ages, antibody levels 
were significantly higher with a single dose following natural infec-
tion than with two BNT162b2 doses, whereas two doses achieved 
similar antibody levels to one dose following natural infection at 
younger and older ages.
Latent class analysis of antibody trajectory in participants with-
out prior infection. We used descriptive latent class mixed models 
to identify evidence for different subgroups of responses after vac-
cination. The best-fitting models identified four classes of antibody 
responses post-vaccination for both vaccines (Fig. 5, Extended 
Data Fig. 9 and Supplementary Table 4). In a ‘plausibly previously 
infected’ group (class 1, navy-blue line, comprising 3.9% of those 
receiving single-dose ChAdOx1 or BNT162b2), anti-spike IgG 
levels started higher pre-vaccination (but below the threshold for 
positivity) and rapidly rose. In a ‘high response’ group (class 2, orange 
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Fig. 1 | Predicted probability of anti-spike Igg positivity by time from first vaccination for comparisons of age by vaccine type and prior infection status. 
The data are from 40,131 participants without prior infection and 5,834 participants with prior infection. a, No prior infection and received one dose of 
ChAdOx1. b, No prior infection and received one dose of BNT162b2. c, No prior infection and received two doses of BNT162b2. d, With prior infection and 
received one dose of ChAdOx1. e, With prior infection and received one dose of BNT162b2. f, For those who received two doses of BNT162b2 without prior 
infection, the chart shows the percentage of participants having had two vaccine doses by each time point (grey, had two doses; blue, had only one dose). 
Different x axis scales reflect different durations of follow-up post-vaccination in the different cohorts. Line colour indicates antibody response predicted 
for ages 20, 40, 60 and 80 years (see Extended Data Fig. 2 for the full model across all ages and comparisons of vaccine type by age). The 95% CIs are 
calculated by prediction ± 1.96 × standard error of prediction.
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respectively), IgG levels increased rapidly and to a higher level before 
plateauing. A ‘medium response’ group (class 3, mid-blue line, 58.7% 
and 27.5% of ChAdOx1 and BNT162b2 recipients) had mean anti-
body levels slightly below the high-response group but still above 
the positivity threshold. Last, participants in a ‘low response’ group 
(class 4, red line) had mean IgG levels below the positivity threshold 
throughout, peaking at ~10 ng ml–1, and their response was delayed. 
A similar percentage, 5.8% and 5.1% of participants receiving the 
ChAdOx1 or BNT162b2 vaccine, respectively, fell in this group. 
Low-response participants were older while high-response partici-
pants were younger for both vaccines (Extended Data Fig. 10). 
Low responders also had a higher proportion of males for the 
ChAdOx1 vaccine and people with long-term health conditions 
for both vaccines (P < 0.001). Many health conditions were more 
common in low responders (Supplementary Table 5), with taking 
immunosuppressants (aOR for class 4 versus class 2 or 3 responses, 
3.91 [95% CI = 2.64–5.78]), rheumatoid arthritis (2.50 [1.66–3.76]), 
chronic liver disease (2.34 [1.06–5.19]), cancer (1.62 [1.31–1.99]), 
taking corticosteroids (1.59 [1.21–2.10]), type 2 diabetes (1.44 
[1.07–1.93]), obesity (body–mass index ≥ 30 kg per m2, 1.25 [1.05–
1.48]) and asthma (1.25 [1.03–1.52]) independently associated with 
low responses.
Table 1 | Predictors of antibody positivity 14–60 days post first vaccination in participants without evidence of prior infection from 
univariable and multivariable logistic regression models





P value OR 95% CI P value OR 95% CI  P value
Agea <0.001 <0.001
 Median 69 67
 IQR 62, 74 58, 73
Sexa <0.001
 Female 2,085 (46.6%) 11,726 (57.2%) 1 (ref)
 Male 2,387 (53.4%) 8,779 (42.8%) 0.65 0.61–0.70 <0.001
Vaccine type <0.001
 One dose BNT162b2 1,323 (29.6%) 9,141 (44.6%) 1 (ref) 1 (ref)
 One dose ChAdOx1 3,058 (68.4%) 10,231 (49.9%) 0.48 0.45–0.52 <0.001 0.47 0.44–0.51 <0.001
 Two doses BNT162b2 91 (2.0%) 1,133 (5.5%) 1.80 1.45–2.26 <0.001 2.11 1.69–2.66 <0.001
Ethnicity <0.001
 White 4,356 (97.4%) 19,529 (95.2%) 1 (ref) 1 (ref)
 Non-white 116 (2.6%) 976 (4.8%) 1.88 1.55–2.29 <0.001 1.54 1.27–1.90 <0.001
Household size <0.001
 1 1,160 (25.9%) 4,704 (22.9%) 1 (ref) 1 (ref)
 2 2,621 (58.6%) 11,900 (58.0%) 1.12 1.04–1.21 0.004 1.10 1.02–1.19 0.02
 3 405 (9.1%) 2,140 (10.4%) 1.30 1.15–1.48 <0.001 1.03 0.90–1.17 0.7
 4 202 (4.5%) 1,217 (5.9%) 1.49 1.27–1.75 <0.001 0.96 0.80–1.14 0.6
 5+ 84 (1.9%) 544 (2.7%) 1.60 1.27–2.04 <0.001 1.01 0.79–1.31 0.9
Deprivation percentile 0.001
 Median 63 64 (10-unit increase) (10-unit increase)
 IQR 37, 82 40, 83 1.22 1.08–1.38 0.001 1.28 1.13–1.46 <0.001
Report working in patient-facing healthcare <0.001
 No 4,386 (98.1%) 19,249 (93.9%) 1 (ref) 1 (ref)
 Yes 86 (1.9%) 1,256 (6.1%) 3.33 2.69–4.18 <0.001 1.63 1.29–2.08 <0.001
Report working in person-facing social care <0.001
 No 4,427 (99.0%) 20,154 (98.3%) 1 (ref) 1 (ref)
 Yes 45 (1.0%) 351 (1.7%) 1.71 1.27–2.37 <0.001 1.00 0.72–1.40 1
Report working in care home (any role) <0.001
 No 4,445 (99.4%) 20,177 (98.4%) 1 (ref) 1 (ref)
 Yes 27 (0.6%) 328 (1.6%) 2.68 1.84–4.06 <0.001 1.24 0.82–1.93 0.3
Report having long-term health condition <0.001
 No 2,404 (53.8%) 13,427 (65.5%) 1 (ref) 1 (ref)
 Yes 2,068 (46.2%) 7,078 (34.5%) 0.61 0.57–0.65 <0.001 0.64 0.60–0.69 <0.001
aThe combined effects of age and sex for the multivariable model are shown in Fig. 2. The 95% CIs are calculated by prediction ± 1.96 × standard error of the prediction; Wald P values are shown. Ref, 
reference category.
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Discussion
In this study based on 45,965 vaccinated participants from a large 
random sample of the UK population, we showed that post-vaccine 
anti-spike IgG responses vary by prior infection status, age, sex, vac-
cine type and number of doses received. In those who were previ-
ously infected, all age groups achieved high antibody responses after 
the first vaccination. In those without evidence of prior infection, 
older participants had lower and slower responses after the first vac-
cine dose than younger participants. Two vaccine doses achieved 
high responses across all age groups, and particularly increased the 
number of older people seroconverting to similar levels to those 
receiving one dose after prior infection, as recently reported in a 
smaller number of younger individuals7. A single dose of ChAdOx1 
resulted in lower absolute antibody levels and slower responses 
compared with a single dose of BNT162b2. However, antibody 
levels after a single dose of BNT162b2 waned over time, whereas 
levels remained approximately constant after a single dose of 
ChAdOx1. Importantly, we did not identify a group who did not 
respond at all to vaccination; however, ~6% of participants were 
low responders to both vaccines, with low responses independently 
associated with several long-term health conditions.
The relative differences in vaccine response by age and previ-
ous infection status are similar to those reported by the REACT-2 
study12 of binary point-of-care lateral flow assay results after a single 
dose of BNT162b2. However, our results showed a much higher 
antibody response than reported in REACT-2, especially in older 
people, despite studying the same UK population. These differences 
probably reflect the lower sensitivity of the assay used in REACT-2, 
despite efforts to adjust for this12. In our study, mean quantitative 
responses were not far from the positivity threshold, particularly 
for older age groups, which demonstrates the challenge in applying 
binary thresholds to what are essentially continuous data. This is 
particularly important given that the antibody levels required for 
protection are still unclear, with a study using the same assay as our 
study identifying a gradient of protection associated with quanti-
tative antibody levels below the positivity threshold following pre-
vious infection15. Our study provides additional comparative data 
on antibody responses following the ChAdOx1 vaccine. Studies 
of healthcare workers also support an inverse association between 
antibody response and age in those receiving a single dose of the 
BNT162b2 vaccine16,17 or the ChAdOx1 vaccine6.
We found in those without evidence of previous infection, at 
older ages, females had a higher probability of being IgG positive 
post-vaccination than males, and females were more likely to be 
in the high-response latent class. Sex differences in antibody levels 
have also been described following natural infection18. These find-
ings are consistent with observations that females generate stron-
ger humoral immunity and greater vaccine efficacy than males19,20. 
However, a UK study of 3,610 healthcare workers (median age of 
41 years) did not find any association between sex and single-dose 
ChAdOx1 or BNT162b2 antibody responses6, which is possibly 
explained by our finding that sex differences in antibody responses 
become more marked above 60 years of age.
Consistent with several previous studies7,8,21, we found that in 
previously infected participants, a single dose of ChAdOx1 or 
BNT162b2 led to high anti-spike IgG antibody positivity and quan-
titative levels. Where vaccine supplies are limited, this supports 
prioritizing those without evidence of previous infection for vacci-
nation and, in particular, delaying or omitting second doses in those 
with robust serological evidence of previous infection in these sce-
narios. We also find that receiving two vaccine doses significantly 
increased seropositivity and antibody levels in older participants, 
but the short-term incremental increase in 20–40 year olds with a 
second vaccine was much smaller, thereby suggesting that older age 
groups should be prioritized for a second vaccination. However, 
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Fig. 2 | Predicted probability of anti-spike Igg positivity after first vaccination in participants without evidence of prior infection from a multivariable 
logistic regression model. Predicted probability with 95% CIs of anti-spike IgG positivity 14–60 days after first vaccination in 24,977 participants without 
evidence of prior infection. a, Predicted probability of anti-spike IgG positivity by age and sex. b, Predicted probability of anti-spike IgG positivity by age 
and vaccine type. Age was fitted using natural cubic spline with four internal knots placed at the 20th, 40th, 60th and 80th percentile (30, 44, 57 and 71 
years) and two boundary knots at the 5th and 95th percentile (19 and 82 years). The 95% CIs were calculated by prediction ± 1.96 × standard error of the 
prediction and are shown as the shaded area. Testing for an interaction between sex and age was performed using a likelihood ratio test (P = 0.02). Values 
are plotted at the reference category for other variables (BNT162b2 one dose (a)/female (b), white ethnicity, index of multiple deprivation = 55, household 
size = 1, did not work in patient-facing healthcare or social care, did not work in a care home, no long-term health condition).
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with seroconversion rates after the first dose vaccination exceed-
ing the reduction in symptomatic infection. Therefore, vaccine effi-
cacy against clinical outcomes as well as antibody responses should 
contribute to prioritization decisions. In a related UK-wide study22 
and a study from Israel23, high levels of protection from infection 
following natural infection were observed that were comparable to 
those seen after two doses of vaccination without prior infection. In 
the latter study23, the authors question whether previously infected 
individuals require vaccination; our data show that vaccination 
does boost antibody responses after previous infection, although 
the impact on protection from infection over varying timescales 
requires further study.
Our latent class analysis identified four distinct types of vaccine 
response. The low-response class was more common in older 
participants and those with long-term health conditions, but com-
prised a similar percentage receiving the different vaccines. Further 
follow-up is needed to identify whether the modest increases in 
antibody levels achieved still lead to some protection against key 
outcomes such as hospitalization, death or onward transmission, 
and to what extent second vaccine doses boost this initial sub-
optimal response. This low-responder group could be identified by 
a negative antibody result on our assay from day 28 post-vaccine. 
Similar underlying latent classes were identified following single 
doses of the two vaccines, with different mean responses overall due 
to different percentages estimated to fall into the high-response and 
medium-response classes for ChAdOx1 and BNT162b2. Further 
studies are also required to assess whether different degrees of 
response are associated with different rates of waning over time and 
protection against clinical outcomes. A recent study of 10,412 of 
long-term care residents showed 65% and 68% protection against 
laboratory-confirmed SARS-CoV-2 infection 28–42 days after vac-
cination with the ChAdOx1 and BNT162b2 vaccines, respectively, 
which suggests that differences in antibody responses may have a 
limited impact on outcomes, at least in the short term24. Similar 
short-term (6 weeks) protection against symptomatic infection, 
hospitalization and death with single doses of both vaccines was 
also seen in adults aged >70 years in England25.
Using data from all participants in the national survey22, 
we found a 76% reduction in symptomatic SARS-CoV-2 infec-
tion following a first vaccine dose, rising to 95% after two doses, 
with no evidence of differences after BNT162b2 and ChAdOx1 
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Fig. 3 | Predicted anti-spike Igg levels by time from first vaccination for comparisons of age by vaccine type and prior infection status. Predicted 
anti-spike IgG levels (mAb45 ng ml–1 equivalent units) by time from first vaccination based on data from 40,131 participants without prior infection and 
5,834 participants with prior infection. a, No prior infection and received one dose of ChAdOx1. b, No prior infection and received one dose of BNT162b2. 
c, No prior infection and received two doses of BNT162b2. d, With prior infection and received one dose of ChAdOx1. e, With prior infection and received 
one dose of BNT162b2. f, For those who received two doses of BNT162b2 without prior infection, the chart shows the percentage of participants having 
had two vaccine doses by each time point (grey, had two doses; blue, had only one dose). Different x axis scales reflect different durations of follow-up 
post-vaccination in the different cohorts. Predicted levels are plotted on a log scale. Black dotted line indicates the threshold of IgG positivity (42 ng ml–1). 
Line colour indicates response predicted for ages 20, 40, 60 and 80 years (see Extended Data Fig. 8 for all ages and Fig. 4 for comparisons of vaccine type 
by age). The 95% CIs are calculated by prediction ± 1.96 × standard error of the prediction.
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antibody titres (and other immunological measurements) are cor-
relates of post-vaccination protection and its duration. Pooled data 
from clinical trials and a post-infection study show a strong rela-
tionship between mean neutralization levels and reported protec-
tion14, estimating that protection from infection is likely to fall over 
250 days (given an estimated 2-month half-life for post-vaccine 
neutralization titres), but with largely preserved protection from 
severe infection. In this current study, antibodies were measured 
in only a subset of survey participants, so data are currently insuf-
ficient to directly estimate the relationship between post-vaccine 
antibody titres and protection from infection. However, previous 
studies provide some indication. For example, using the same assay, 
post-infection antibody titres of 28 ng ml–1 mAb45 equivalents (or 
7 million fluorescence units) were associated with 50% protection 
from any subsequent PCR-positive result in healthcare workers15. 
Most of those vaccinated in this study achieved levels of >28 ng ml–1, 
including at older ages, for example, mean 73 and 113 ng ml–1 for 
80 year olds 28 days after the first ChAdOx1 or BNT162b2 dose, 
respectively. Only ~6% of individuals were in the low-responder 
latent class, with peak antibody levels reaching only ~10 ng ml–1.
Study limitations include currently insufficient data to analyse 
responses following two doses of ChAdOx1 (533 participants 
without and 66 with prior infection). Data on antibody responses 
between 8 and 12 weeks after the first dose without a second dose 
were also limited. Further follow-up will be required to assess the 
duration of responses to all vaccines and how variations in the inter-
val between first and second doses affects this. Although our study 
is representative of those vaccinated to date in the UK, vacci nation 
prioritization means that we have fewer data on healthy younger 
adults. We show that multiple long-term health conditions are 
associated with lower antibody responses, but additional studies 
are required to understand their significance for vaccine protec-
tion. Our study assesses responses using a single assay; however, 
responses were calibrated to a monoclonal antibody such that these 
can be readily compared with other studies. Neutralizing antibody 
and T-cell responses were not assayed in this study. However, a 
recent much smaller study of T-cell responses post-vaccination in 
healthcare workers found qualitatively similar findings26.
In summary, in this population-representative study of indi-
vi duals vaccinated to date in the UK, vaccination results in 
detectable SARS-CoV-2 anti-spike IgG levels in the majority of indi-
viduals after first vaccination. High rates of seroconversion and high 
quantitative antibody levels following one dose of vaccine after 
previous infection and in younger previously uninfected indivi-
duals potentially supports single dose or delayed second dose vacci-
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Fig. 4 | Predicted anti-spike Igg levels by time from first vaccination for comparisons of vaccine type and prior infection status by age. a–d, Predicted 
anti-spike IgG levels (mAb45 ng ml–1 equivalent units) by time from first vaccination based on data from 40,131 participants without prior infection  
and 5,834 participants with prior infection. Data shown for 20 year olds (a), 40 year olds (b), 60 year olds (c) and 80 year olds (d). Black dotted line 
indicates the threshold of IgG positivity (42 ng ml–1). Line colour indicates predicted response for the different vaccine type and prior infection status  
(full models shown in Extended Data Fig. 8, plotted by vaccine in Fig. 3). The 95% CIs are calculated by prediction ± 1.96 × standard error of the prediction. 
Data identical to Fig. 3, but Fig. 3 represent age rather than vaccine type.
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potential for this to lead to antigenic evolution requires investiga-
tion27. Further data from this study and others will be needed to 
assess the extent to which quantitative antibody levels can be used 
as a correlate of vaccine-mediated protection.
Methods
Population and data. We used data from the UK’s Office for National Statistics 
(ONS) COVID-19 Infection Survey (ISRCTN21086382) from 26 April 2020 to 6 
April 2021. The survey randomly selects private households on a continuous basis 
from address lists and previous surveys conducted by the ONS or the Northern 
Ireland Statistics and Research Agency to provide a representative sample across 
the four countries constituting the UK (England, Wales, Northern Ireland and 
Scotland). Following verbal agreement to participate, a study worker visited 
each household to take written informed consent. This consent was obtained 
from parents/carers for those aged 2–15 years, while those aged 10–15 years also 
provided written assent. Children aged <2 years were not eligible for the study. At 
the first visit, participants were asked for (optional) consent for follow-up visits 
every week for the next month, then monthly for 12 months from enrolment. For 
a random 10% of households, those aged ≥16 years were invited to provide blood 
monthly for serological testing from enrolment. Nose and throat swabs were taken 
from all consenting household members, according to the follow-up schedule 
they agreed to at enrolment. Any individual aged ≥16 years from a household 
where anyone tested positive on a nose and throat swab was also invited to provide 
blood at all subsequent monthly visits. Participants provided survey data on 
sociodemographic characteristics and vaccination status. Details on the sampling 
design are provided elsewhere28. The study protocol is available at https://www.ndm. 
ox.ac.uk/covid-19/covid-19-infection-survey/protocol-and-information-sheets. 
The study received ethical approval from the South Central Berkshire B Research 
Ethics Committee (20/SC/0195).
Vaccination data were reported by participants to the COVID-19 Infection 
Survey and obtained from linkage to the National Immunisation Management 
Service, which holds a database of all individuals vaccinated in the National 
Health Service COVID-19 vaccination programme in England. Similar linked 
administrative data were not available for Northern Ireland, Scotland or Wales. 
Information on the date, doses and type of vaccination were included in the dataset.
Only participants who received at least one dose of the ChAdOx1 or BNT162b2 
vaccine were included; other vaccines were very rarely reported. Participants aged 
≥16 years who had received at least one dose of vaccine from 8 December 2020 
onwards with one or more antibody measurements from 91 days before their first 
vaccination date up until 6 April 2021 were included.
Laboratory testing. SARS-CoV-2 antibody levels were measured using an ELISA 
detecting anti-trimeric spike IgG developed by the University of Oxford28,29. All 
testing was performed at the University of Oxford. Normalized results are reported 
in ng ml–1 of mAb45 monoclonal antibody equivalents. Up to 26 February 2021, 
the assay was performed using a fluorescence detection mechanism as previously 
described29, using a threshold of 8 million units to identify positive samples. 
Subsequent testing was performed with a CE-marked version of the assay, the  
Thermo Fisher OmniPATH 384 Combi SARS-CoV-2 IgG ELISA, which uses the  
same antigen, with a colorimetric detection system. mAb45 is the manufacturer- 
provided monoclonal antibody calibrant for this quantitative assay. To allow  
conversion of fluorometrically determined values in arbitrary units, 3,840 samples  
were run in parallel on both systems and compared. A piece-wise linear regression  
was used to generate the following conversion formula: log10(mAb45 units) =  
0.221738 + 1.751889 × 10−7 × fluorescence units + 5.416675 ×10−7 × (fluorescence 
units > 9,190,310) × (fluorescence units − 9,190,310).
A threshold of ≥42 ng ml–1 was used to identify IgG-positive samples, corres-
ponding to the 8 million units with fluorescence detection. In this analysis, 
measurements <2 ng ml–1 (395 observations, 0.4%) and >500 ng ml–1  
(7,707 observations, 7%) were truncated at 2 and 500 ng ml–1, respectively.
PCR assays of combined nose and throat swabs were undertaken using 
the Thermo Fisher TaqPath SARS-CoV-2 assay at high-throughput national 
‘Lighthouse’ laboratories in Glasgow and Milton Keynes (up until 8 February 
2021). PCR outputs were analysed using UgenTec FastFinder 3.300.5, with an 
assay-specific algorithm and decision mechanism that allows conversion of 
amplification assay raw data into test results with minimal manual intervention. 
Samples are called positive if at least a single N-gene and/or ORF1ab are detected 
(although S-gene cycle threshold (Ct) values are determined, S-gene detection 
alone is not considered sufficient to call a sample positive28) and PCR traces  
exhibit an appropriate morphology.
Statistical analysis. Participants with a SARS-CoV-2 PCR-positive nose/
throat swab or a prior positive anti-spike IgG antibody result at any time before 
vaccination were considered to have been previously infected with SARS-CoV-2, 
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Fig. 5 | Predicted anti-spike Igg trajectory in participants without prior infection by class identified from latent class mixed models. Predicted anti-spike 
IgG trajectory in 36,518 participants without prior infection by class identified from latent class mixed models, using data from 14 days before vaccination 
to the 90th percentile of the observed time points after vaccination. a, One dose ChAdOx1 vaccine and no evidence of prior infection (N = 22,424 
participants). b, One dose BNT162b2 vaccine and no evidence of prior infection (N = 14,094 participants). Black dotted line indicates the threshold of IgG 
positivity (42 ng ml–1). The 95% CIs are calculated by Monte Carlo approximation of the posterior distribution of the predicted values. The distribution 
of factors by class membership is shown in Supplementary Table 4. Class 1 = plausibly previously infected group (3.9% ChAdOx1, 3.9% BNT162b2), 
2 = high-response group (31.6% ChAdOx1, 63.5% BNT162b2), 3 = medium-response group (58.7% ChAdOx1, 27.5% BNT162b2), 4 = low-response group 
(5.8% ChAdOx1, 5.1% BNT162b2).
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results from the survey were included in this classification, but not self-reported 
PCR or lateral flow test results obtained outside the study. We used multivariable 
logistic and linear generalized additive models to investigate binary (positive/
negative) and quantitative (log10(mAb45 units)) anti-spike IgG antibody 
measurements after the first vaccination. Given the prior hypothesis that response 
to vaccination would vary differentially by age and time according to vaccine type 
and prior infection, we built separate models by vaccine type, for those receiving 
one or two vaccinations, and by prior infection status. For participants receiving 
one vaccine dose, four models were fitted, for each vaccine and in those with and 
without evidence of prior infection. Two-dose models were only fitted for those 
receiving BNT162b2 without evidence of prior infection, as the sample sizes 
were small for other groups: 315 participants with prior infection receiving two 
BNT162b2 doses; 533 participants without prior infection receiving two ChAdOx1 
doses; 66 participants with prior infection receiving two ChAdOx1 doses 
(Extended Data Fig. 1).
Models were adjusted for participant age using a tensor product of B-splines 
to allow for nonlinearity and interaction between age and time since vaccination. 
The smoothing penalty was selected using fast restricted maximum likelihood as 
implemented in the mcgv R package. We included a random intercept for each 
participant to account for repeated measurements using a random effect smoother 
with the number of basis functions equal to the number of participants. The 95% 
CIs were calculated using the following formula: prediction ± 1.96 × standard error 
of prediction. The date of the first vaccination was set as t = 0. For those with no 
prior evidence of infection, we truncated time at t = 0 and t = −14 for logistic and 
linear models, respectively (t = −14 for linear models to estimate IgG baseline 
pre-vaccination). We excluded measurements taken after the 90th percentile of 
observed time points for all models to avoid undue influence from outliers at late 
time points. Any participant receiving a second BNT162b2 dose after the 90th 
percentile for the single BNT162b2 dose group (61 days) was censored at this time 
point and included in the one-dose group (1,383 (3%) participants were censored 
in this way). Age was truncated at 85 years in all analyses to avoid outlier influence.
To investigate predictors of antibody response in those without prior evidence 
of infection, we considered the latest antibody measurement per participant 
between 14 and 60 days after the first vaccine. We used multivariable logistic 
regression to examine the association between antibody positivity and vaccine 
type and doses received by this measurement time, demographic factors (age, sex 
and ethnicity), household size, deprivation ranking (index of multiple deprivation 
in England and equivalent percentile ranking in Wales, Northern Ireland and 
Scotland), whether the participant reported working in patient-facing healthcare 
or social care, whether they reported working in a care home (any role), and 
whether they reported having a long-term health condition. Nonlinearity in age 
was accounted for using restricted natural cubic splines with internal knots at the 
20th, 40th, 60th and 80th percentiles of unique values, and boundary knots at 5th 
and 95th percentiles. We tested for and added interactions between age and other 
variables if the interaction P value was <0.05.
For those without evidence of prior infection who received a single dose 
of vaccine, we also investigated whether we could identify distinct patterns of 
antibody responses, using latent class mixed models to identify subgroups with 
different antibody trajectories after the first vaccination. Natural cubic splines 
(internal knots at the 20th, 40th, 60th and 80th percentiles of unique values, 
and boundary knots at 5th and 95th percentiles) were used to model time since 
vaccination as a fixed effect and a random intercept was added to account for 
individual variability. Within-class between-individual heterogeneity may also 
be present in the trajectories; however, models accounting for random slopes 
failed to converge. Age with natural cubic splines (same as above), sex, reported 
long-term health conditions and whether the participant was a healthcare worker 
were included as covariates for class membership. The 95% CI of the estimation 
was calculated by a Monte Carlo approximation of the posterior distribution 
of the predicted values, using the 2.5% and 97.5% percentiles. The number of 
classes was determined by minimizing the Bayesian information criterion for each 
vaccine, and then fitting the maximum number of classes (four) to both groups for 
comparability.
To compare prevalence of long-term health conditions across different 
subgroups identified, participants from England were linked to the General 
Practice Extraction Service Data for Pandemic Planning and Research via their 
NHS number (equivalent data not available for participants from the Devolved 
Administrations (Wales, Northern Ireland and Scotland)). A range of pre-existing 
conditions across organ systems were identified from diagnosis codes over the 
10-year look-back period 1 January 2010 to 24 January 2020 (the date of the first 
known case of COVID-19 in the UK). Body–mass index was the most recently 
recorded measurement over the look-back period, without imputation. Participants 
were recorded as being on antihypertensive medication, diabetes medication, 
corticosteroids or immunosuppressants if they were prescribed these treatments 
within 90 days of the end of the look-back period. All clinical variables were 
derived from primary care records only; hospital admissions data were not used.
Analyses were performed using the tidyverse (v.1.3.0), mgcv (v.1.8-31), splines 
(v.3.6.1), lcmm (v.1.9.2), ggeffects (v.0.14.3), sandwich (v.3.0-0), arsenal (v.3.4.0), 
emmeans (v.1.5.1), cowplot (v.1.1.0), gmodels (v.2.18.1) and mgcViz (v.0.1.6)) 
libraries in R (v.3.6). Model diagnostics used residual checks for generalized 
additive models, including distributions and quantile–quantile plots using check.
gamViz, which showed normally distributed residuals but with some skew due to 
the assay upper limit of 500 ng ml–1. For the logistic model for antibody response 
14–60 days post-vaccination, the C-statistic showed modest discriminatory power 
(0.66), but there was no evidence of misspecification (Homer–Lemeshow P = 1.00).
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Data are still being collected for the COVID-19 Infection Survey. De-identified 
study data are available for access by accredited researchers in the ONS Secure 
Research Service (SRS) for accredited research purposes under part 5, chapter 5 
of the Digital Economy Act 2017. For further information about accreditation, 
contact Research.Support@ons.gov.uk or visit the SRS website. Source data are 
provided with this paper.
Code availability
A copy of the analysis code is available at https://github.com/jiaweioxford/
COVID19_vaccine_antibody_response.
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Extended Data Fig. 1 | Flowchart of the study cohort. N represents the number of participants, and n represents the number of antibody measurements.
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Extended Data Fig. 2 | See next page for caption.
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Extended Data Fig. 2 | Predicted probability of anti-spike Igg positivity by time from first vaccination based on data from 40,131 participants without 
prior infection and 5,834 participants with prior infection. a, 20-year-old. b, 40-year-old. c, 60-year-old. d, 80-year-old. Line colour indicates different 
vaccine type and prior infection status. The 95% confidence intervals are calculated by prediction ± 1.96*standard error of the prediction. Data identical to 
Fig. 1, but Fig. 1 panels represent age rather than vaccine type as here. e, Predicted probability of anti-spike IgG positivity by time from first vaccination and 
age, according to vaccine type and prior infection status (full model). Predictions shown for specific ages in Fig. 1. Observed data in Extended Data Fig. 3–7.
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Extended Data Fig. 3 | Percentage (95% CI) anti-spike Igg positive by days after first vaccination in 23,368 participants receiving a single dose of 
ChAdOx1 vaccine and without evidence of prior infection. Results were divided into four age groups: 16–34, 35–54, 55–74 and >75 years. Exact binomial 
test was performed to obtain the 95% confidence intervals (shown as ‘error bars’). Numbers above the x-axis represent positive number/total number, 
and the percentage of positivity (%).
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Extended Data Fig. 4 | Percentage (95% CI) anti-spike Igg positives by days after first vaccination in 3,767 participants receiving a single dose of 
ChAdOx1 vaccine and with evidence of prior infection. Results were divided into four age groups: 16–34, 35–54, 55–74 and >75 years. Exact binomial test 
was performed to obtain the 95% confidence intervals (shown as ‘error bars’). Numbers above the x-axis represent positive number/total number, and the 
percentage of positivity (%).
NATURE MICROBIOlOgY | www.nature.com/naturemicrobiology
ArticlesNATuRE MICROBIOlOGy
Extended Data Fig. 5 | Percentage (95% CI) anti-spike Igg positives by days after first vaccination in 14,894 participants receiving a single dose of 
BNT162b2 vaccine and without evidence of prior infection. Results were divided into four age groups: 16–34, 35–54, 55–74 and >75 years. Exact binomial 
test was performed to obtain the 95% confidence intervals (shown as ‘error bars’). Numbers above the x-axis represent positive number/total number, 
and the percentage of positivity (%).
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Extended Data Fig. 6 | Percentage (95% CI) anti-spike Igg positives by days after first vaccination in 2,067 participants receiving a single dose of 
BNT162b2 vaccine and with evidence of prior infection. Results were divided into four age groups: 16–34, 35–54, 55–74 and >75 years. Exact binomial 
test was performed to obtain the 95% confidence intervals (shown as ‘error bars’). Numbers above the x-axis represent positive number/total number, 
and the percentage of positivity (%).
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Extended Data Fig. 7 | Percentage (95% CI) anti-spike Igg positives by days after first vaccination in 1,869 participants receiving two doses of 
BNT162b2 vaccine and without evidence of prior infection. Results were divided into four age groups: 16–34, 35–54, 55–74 and >75 years. Exact binomial 
test was performed to obtain the 95% confidence intervals (shown as ‘error bars’). Numbers above the x-axis represent positive number/total number, 
and the percentage of positivity (%).
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Extended Data Fig. 8 | Predicted anti-spike Igg levels (ng/ml) by time from first vaccination and age based on data from 40,131 participants without 
prior infection and 5,834 participants with prior infection, according to vaccine type and prior infection status (full model). Predictions shown for 
specific ages in Fig. 3.
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Extended Data Fig. 9 | Individual trajectories by classes identified from latent class mixed models for single dose ChAdOx1 and BNT162b2 vaccine.  
In Class 1 and Class 4, all participants were plotted (ChAdOx1-Class 1: N = 867, Class 4: N = 1297. BNT162b2- Class 1: 547, Class 4: 720). In Class 2 and 3, 
1,000 randomly selected participants were plotted for visualisation due to the large number. Colours: navy blue, Class 1; orange, Class 2; mid blue, Class 3; 
red, Class 4.
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Extended Data Fig. 10 | Age distribution by classes identified from latent class mixed models for single dose ChAdOx1 (N = 22,424) and BNT162b2 
(N = 14,094) vaccines. 1 = ’plausibly previously infected’ group, 2 = ’high response’ group, 3 = ’medium response’ group, 4 = ’low response group’. Same 
area for each violin, see Supplementary Table 4 for numbers in each group. For the box and whisker inserts: centre line, median; box limits, upper and  
lower quartiles; whiskers, 1.5x interquartile range; points, outliers. Colours: navy blue, Class 1; orange, Class 2; mid blue, Class 3; red, Class 4.
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